Regen BioPharma, Inc. Completes Preclinical Experimentation for Its siRNA NR2F6 Checkpoint Inhibitor

Company is Currently Preparing IND for New Cancer Immuno-Therapy Drug SAN DIEGO, February 24, 2016, RGBP /PRNewswire/ Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach. Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with the FDA for testing of this approach in cancer patients. Dr. Kesari is Director of Neuro-Oncology, Professor of Neurosciences and Chairman of the Department of Translational Neuro-Oncology and Neuro-Therapeutics at the John Wayne Cancer Center. The experiments revealed that administration of Regen s proprietary gene silencing compounds triggered cells of the immune system to profoundly produce growth factors such as interleukin-17 and interleukin-18. These factors are critical to inducing an anticancer immune response. The


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: